Provided by Tiger Trade Technology Pte. Ltd.

Rhythm Pharmaceuticals Inc.

92.73
-5.3400-5.45%
Post-market: 92.72-0.0097-0.01%16:11 EST
Volume:1.32M
Turnover:122.46M
Market Cap:6.23B
PE:-29.86
High:97.81
Open:96.66
Low:90.84
Close:98.07
52wk High:122.20
52wk Low:45.91
Shares:67.21M
Float Shares:53.42M
Volume Ratio:1.73
T/O Rate:2.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1057
EPS(LYR):-4.3376
ROE:-85.79%
ROA:-26.74%
PB:41.88
PE(LYR):-21.38

Loading ...

Stock Track | Rhythm Pharmaceuticals Plummets 5.65% Following Oppenheimer Downgrade

Stock Track
·
Nov 05, 2025

Rhythm Pharmaceuticals Inc. : Oppenheimer Cuts to Perform From Outperform

THOMSON REUTERS
·
Nov 05, 2025

Oppenheimer downgrades Rhythm Pharmaceuticals (RYTM) to a Hold

TIPRANKS
·
Nov 05, 2025

Rhythm Pharmaceuticals Inc : TD Cowen Raises Target Price to $120 From $110

THOMSON REUTERS
·
Nov 05, 2025

Stock Track | Rhythm Pharmaceuticals Plummets 9.92% as Q3 Earnings Miss Expectations

Stock Track
·
Nov 04, 2025

Earnings Flash (RYTM) Rhythm Pharmaceuticals Posts Q3 Net Loss $0.82 a Share, vs. FactSet Est of $0.66 Loss

MT Newswires Live
·
Nov 04, 2025

BRIEF-Rhythm Pharmaceuticals Q3 Net Income USD -52.904 Million Vs. IBES Estimate USD -45.5 Million

Reuters
·
Nov 04, 2025

Rhythm Pharmaceuticals Q3 EPS $(0.82) Misses $(0.73) Estimate, Sales $51.298M Beat $50.705M Estimate

Benzinga
·
Nov 04, 2025

Rhythm Pharmaceuticals Q3 Product Revenue USD 51.298 Million

THOMSON REUTERS
·
Nov 04, 2025

Rhythm Pharmaceuticals Q3 Basic EPS USD -0.82

THOMSON REUTERS
·
Nov 04, 2025

Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update

THOMSON REUTERS
·
Nov 04, 2025

Rhythm Pharmaceuticals price target raised to $128 from $122 at BofA

TIPRANKS
·
Oct 22, 2025

BofA Securities Adjusts Rhythm Pharmaceuticals Price Target to $128 From $122, Maintains Buy Rating

MT Newswires Live
·
Oct 22, 2025

Rhythm Pharmaceuticals Inc. to Report Third Quarter 2025 Financial Results

Reuters
·
Oct 22, 2025

Rhythm Pharmaceuticals price target lowered to $139 from $157 at Goldman Sachs

TIPRANKS
·
Oct 17, 2025

Rhythm Pharmaceuticals Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Oct 17, 2025

Morgan Stanley Raises Price Target on Rhythm Pharmaceuticals to $129 From $122, Keeps Overweight Rating

MT Newswires Live
·
Oct 16, 2025

Septerna Inc. Appoints Biotechnology Veteran Keith Gottesdiener, M.D., to Board of Directors as Chair of Newly Formed R&D Committee

Reuters
·
Sep 30, 2025

Rhythm Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Sep 29, 2025

Rhythm Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $110 From $100

THOMSON REUTERS
·
Sep 29, 2025